Entrada Therapeutics Inc (TRDA)
17.85
-1.19
(-6.25%)
USD |
NASDAQ |
Nov 15, 16:00
17.81
-0.04
(-0.22%)
After-Hours: 20:00
Entrada Therapeutics Research and Development Expense (TTM): 120.19M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 120.19M |
| June 30, 2024 | 111.12M |
| March 31, 2024 | 105.39M |
| December 31, 2023 | 99.88M |
| September 30, 2023 | 87.28M |
| June 30, 2023 | 84.04M |
| March 31, 2023 | 73.99M |
| Date | Value |
|---|---|
| December 31, 2022 | 66.61M |
| September 30, 2022 | 63.29M |
| June 30, 2022 | 54.84M |
| March 31, 2022 | 45.42M |
| December 31, 2021 | 35.93M |
| September 30, 2021 | 30.22M |
| June 30, 2021 | 25.41M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
25.41M
Minimum
Jun 2021
120.19M
Maximum
Sep 2024
71.69M
Average
70.30M
Median
Research and Development Expense (TTM) Benchmarks
| Catalyst Pharmaceuticals Inc | 10.82M |
| Vertex Pharmaceuticals Inc | 3.456B |
| Assembly Biosciences Inc | 49.97M |
| Sarepta Therapeutics Inc | 800.09M |
| Regenxbio Inc | 213.82M |